Peer Review: Eyeing a $350M venture fund, Nextech recruits Third Rock’s Jakob Loven for the team
Nextech Invest closed its fourth oncology venture fund in 2014 with $64 million, putting it into play at a transatlantic group of cancer drug developers. But this time around, they’re going for $350 million for fund five, and they’ve recruited a former Third Rock alum — Jakob Loven — as a new partner to help manage that investment.
Loven was on the founding Third Rock team that helped set up Relay Pharmaceuticals, a startup focused on protein dynamics, right after he was founding scientist at Syros. And he crossed the globe to get his education: University of Cambridge, the Karolinska Institute and the Whitehead Institute for his postdoc.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.